Share on Instagram  
Background Image

#iconohash presents #bcsm

Scroll down for the #bcsm conversation report for July 18th, 2018 EST.

iconohash

the world's conversation archive

#bcsm for July 18th, 2018EST

01
98th

coming together

When it comes to participants, we ranked 98th among 544 conversations.

99th

participating

In terms of the number of posts, we ranked 99th out of 544 conversations that took place.

69th

amplification

This conversation ranked 69th out of 544 in terms of the amplification of ideas & content.

how we participated. Here's how participants reacted & engaged each other

Reactions
62%

Amplified

There were 36 reshares, 62% of posts, during the course of the conversation.

0%

Engaged

0% of participants in this conversation engaged each other 0 times.

64%

Content

64% of participants in this conversation shared a total of 8 unique pieces of content.

quick facts.

Here are the basic facts of the conversation for for July 18th, 2018.

0
Active
Participants
0
Posts
Total

meet the influencers the movers and shakers of #bcsm

02

the top of the list. Top influencers in the chat

IMPACT
@OncLive

@OncLive

OncLive.com
Healthcare publisher of oncology focused journals, videos, panel discussions, and much more that run the gamut of oncology care and management.

@METUPorg

@METUPorg

METUP
METUP is committed to changing the landscape of metastatic cancer through direct action.

@BreastAdvocate

@BreastAdvocate

Breast Advocate
Free #BreastCancer #Surgery #SharedDecisionMaking App for #Survivors, #Thrivers and #Previvors. Co-created by breast cancer specialists and patient advocates.

moving the conversation.

Without these participants, this conversation could not happen.

about the participants. let's take a look at everyone who show'd up

03

top professions what are they doing when they're not in #bcsm

insight

  the top participating professions
out of 13 total

research
director
journalist
editor
writer

gender an estimation of what the gender break down looks like
= 1 men or women

insight

Women

Men

about the content. the best content that was shared

04
FDA Expands Ribociclib Breast Cancer Approval Under New Pilot Programs
The FDA has approved upfront ribociclib for use in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer. The agency also approved the CDK 4/6 inhibitor for use in combination with fulvestrant for the treatment of postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer, in the frontline setting or after disease progression on endocrine therapy.<
Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast Cancer
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

chat growth how is #bcsm growing over time?

05

want more? are you interested in the full data analysis for this chat? Full transcript? Longer view at chat growth?

Email us today at research@iconohash.com or schedule a tour of our custom reports. We'll be happy to work with you. We can provide the raw data or custom reports on a scheduled basis. Full data analysis includes in-depth profile data, chat growth analysis, chat reach, influence reach, location profiles, and content profiles. Full reports are delivered via sharable web-based reports or beautiful PDFs, if you prefer to print and distribute.